Why Vir Biotechnology shares are trading lower today

What happened?

Shares of Vir Biotechnology fell 18.8% in the afternoon session after the company announced, in a company press release, the pricing of an underwritten public offering of 15 million shares of common stock at $10 per share. 

Vir Biotechnology expects gross proceeds of $150 million from the transaction before deducting underwriting discounts, commissions, and estimated offering expenses. The offering includes 15 million common shares. Selling newly issued shares increases the total number of shares outstanding, which dilutes existing shareholders' equity interests. Equity offerings priced at a set valuation can also create downward pressure on the stock.

The shares closed the day at $9.96, down 17.7% from the previous close.

What is the market telling us

Vir Biotechnology’s shares are extremely volatile and have had 41 moves greater than 5% over the last year. But moves this big are rare even for Vir Biotechnology and indicate this news significantly impacted the market’s perception of the business.

Vir Biotechnology is up 68% since the beginning of the year, but at $9.98 per share, it is still trading 26.9% below its 52-week high of $13.65 from November 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Vir Biotechnology’s shares 5 years ago would now be looking at only $303.44.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.